PMID- 25964777
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150512
LR  - 20181113
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 6
DP  - 2015
TI  - Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation.
PG  - 59
LID - 10.3389/fendo.2015.00059 [doi]
LID - 59
AB  - Insulin-like growth factor (IGF) signaling is fundamental for growth and 
      survival. A large body of evidence (laboratory, epidemiological, and clinical) 
      implicates the exploitation of this pathway in cancer. Up to 50% of breast tumors 
      express the activated form of the type 1 insulin-like growth factor receptor 
      (IGF1R). Breast cancers are categorized into subtypes based upon hormone and 
      ERRB2 receptor expression and/or gene expression profiling. Even though IGF1R 
      influences tumorigenic phenotypes and drug resistance across all breast cancer 
      subtypes, it has specific expression and function in each. In some subtypes, 
      IGF1R levels correlate with a favorable prognosis, while in others it is 
      associated with recurrence and poor prognosis, suggesting different actions based 
      upon cellular and molecular contexts. In this review, we examine IGF1R expression 
      and function as it relates to breast cancer subtype and therapy-acquired 
      resistance. Additionally, we discuss the role of IGF1R in stem cell maintenance 
      and lineage differentiation and how these cell fate influences may alter the 
      differentiation potential and cellular composition of breast tumors.
FAU - Farabaugh, Susan M
AU  - Farabaugh SM
AD  - Department of Pharmacology and Chemical Biology, University of Pittsburgh , 
      Pittsburgh, PA , USA ; Women's Cancer Research Center, Magee-Womens Research 
      Institute, University of Pittsburgh Cancer Institute, University of Pittsburgh , 
      Pittsburgh, PA , USA.
FAU - Boone, David N
AU  - Boone DN
AD  - Department of Pharmacology and Chemical Biology, University of Pittsburgh , 
      Pittsburgh, PA , USA ; Women's Cancer Research Center, Magee-Womens Research 
      Institute, University of Pittsburgh Cancer Institute, University of Pittsburgh , 
      Pittsburgh, PA , USA.
FAU - Lee, Adrian V
AU  - Lee AV
AD  - Department of Pharmacology and Chemical Biology, University of Pittsburgh , 
      Pittsburgh, PA , USA ; Women's Cancer Research Center, Magee-Womens Research 
      Institute, University of Pittsburgh Cancer Institute, University of Pittsburgh , 
      Pittsburgh, PA , USA ; Department of Human Genetics, University of Pittsburgh , 
      Pittsburgh, PA , USA.
LA  - eng
GR  - R01 CA094118/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20150424
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC4408912
OTO - NOTNLM
OT  - ER+
OT  - ERBB2+
OT  - IGF1R
OT  - breast cancer subtypes
OT  - lineages
OT  - luminal
OT  - triple negative
EDAT- 2015/05/13 06:00
MHDA- 2015/05/13 06:01
PMCR- 2015/01/01
CRDT- 2015/05/13 06:00
PHST- 2015/02/15 00:00 [received]
PHST- 2015/04/07 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/05/13 06:01 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2015.00059 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2015 Apr 24;6:59. doi: 10.3389/fendo.2015.00059. 
      eCollection 2015.